Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma, a biotechnology company that is developing treatments for adrenomyeloneuropathy (AMN), human immunodeficiency virus (HIV), multiple sclerosis (MS) and pain, has received $244,479 grant under the Qualifying Therapeutic Discovery Project (QTPD) Program.
Subscribe to our email newsletter
Nutra Pharma is expected to use the grant proceeds to support additional clinical work on its pain treatments.
Nutra Pharma chairman and CEO Rik Deitsch said that it was an honor to receive the grant and to be recognised by the US Federal Government for their work developing new analgesics.
"We intend to use the proceeds from this grant to support our ongoing clinical development program for our pain relievers, which include Cobroxin and Nyloxin," Deitsch said.
The QTDP Program was enacted in 2010 by the US Congress as part of the Patient Protection and Affordable Care Act.